Reach Us +1-217-403-9671
Quality Assurance System For Chinese Clinical Studies Of Chinese Clinical Trials Registry | 8293
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Quality assurance system for Chinese clinical studies of Chinese clinical trials registry

International Conference and Exhibiton on Pharmaceutical Regulatory Affairs

Taixiang Wu

ScientificTracks Abstracts: JBB

DOI: 10.4172/0975-0851.1000107

A s a national public clinical trial registry and a recognized Primary Registry of WHO, Chinese Clinical Trial Registry (ChiCTR) takes the respon sibility to dissimilate the knowledge of clinical trial transparency which is an import ant ethics issue of medical studies involving human, and to promote the quality of medical studies in China. Th e ChiCTR had developed three key points to ensure the quality of clinical studies include: 1. Register a clinical study involving human before recruiting the fi rst participants; 2. Real-time monitoring system: eCRF public system; 3. Good reporting the results. We have developed ideas: 1. to register clinical studies is the ethics responsibility and obligation of trialists but not for the purpose of publication; 2. a clinical study is a public event itself which needs public population to participate, and the results may be used to public population service. Th erefore, public have the right to know how the study is processing
Taixiang Wu is the administrator of Chinese Clinical Trials Registry, a primary registry of WHO, a pioneer of clinical trial transparence in China. He has published more than 130 papers in reputed journals and serving as an editorial board member and peer reviewer of repute.
Relevant Topics